BMS – Consensus statement

2018 ◽  
Vol 24 (3) ◽  
pp. 133-138 ◽  
Author(s):  
Joan Pitkin ◽  
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Consensus Statement ◽  
Hormone Replacement ◽  
Treatment Modalities ◽  
Vaginal Estrogen ◽  
Urogenital Atrophy ◽  
New Treatment

Urogenital atrophy is more common than it would first appear and women do not always seek advice and guidance. Confusion still exists between systemic hormone replacement therapy (HRT) and local estrogen preparations but new treatment modalities have emerged that extend the range of options beyond lubricants, moisturisers and vaginal estrogen preparations.

Managing the menopause - British Menopause Society Council consensus statement on hormone replacement therapy

2003 ◽  
Vol 9 (3) ◽  
pp. 129-131 ◽  
Author(s):  
Joan Pitkin ◽  
Margaret C P Rees ◽  
Sarah Gray ◽  
Mary Ann Lumsden ◽  
John Stevenson ◽  
...  
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Consensus Statement ◽  
Hormone Replacement

scholarly journals New Aspects of Melasma/Novi aspekti melazme

2014 ◽  
Vol 6 (1) ◽  
pp. 5-18 ◽  
Author(s):  
Katerina Damevska
Keyword(s):  
Hormone Replacement Therapy ◽  
Recent Progress ◽  
Hormone Replacement ◽  
Treatment Strategies ◽  
Uv Exposure ◽  
Treatment Modalities ◽  
New Treatment ◽  
Topical Medications ◽  
Cosmetic Problem ◽  
Condition Today

Abstract Melasma is a common cosmetic problem and its severity ranges from minor pigmentation during pregnancy that resolves spontaneously, to a chronic, troublesome, disfiguring condition. Today, there are various treatment modalities for melasma, providing a different success rate. The need for an effective treatment for melasma is becoming more and more significant probably due to the current lifestyles with increased UV exposure, broad use of hormones for contraception and hormone replacement therapy, as well as increasing esthetic demands. The mainstay of treatment is regular use of sunscreens along with topical medications suppressing melanogenesis. This review summarizes recent progress in understanding the pathophysiology of melasma and implications for new treatment strategies.

Managing the menopause: British Menopause Society Council consensus statement on hormone replacement therapy

2005 ◽  
Vol 11 (4) ◽  
pp. 152-156 ◽  
Author(s):  
Joan Pitkin ◽  
Margaret C P Rees ◽  
Sarah Gray ◽  
Mary Ann Lumsden ◽  
Jo Marsden ◽  
...  
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Women's Health ◽  
Health Professionals ◽  
Consensus Statement ◽  
Hormone Replacement ◽  
Treatment Choice ◽  
British National Formulary ◽  
National Formulary ◽  
Health Initiative

The British Menopause Society Council aims to help health professionals inform and advise women about the menopause. This guidance regarding estrogen-based hormone replacement therapy (HRT), including tibolone, which is classified in the British National Formulary as HRT, responds to the results and analysis of the randomized Women's Health Initiative studies and the observational Million Women Study. Treatment choice should be based on up-to-date information and targeted to individual women's needs. HRT still offers the potential for benefit to outweigh harm, providing the appropriate regimen has been instigated in terms of dose, route and combination.

BMS consensus statement for primary prevention of coronary heart disease in women

2019 ◽  
Vol 25 (2) ◽  
pp. 64-69 ◽  
Author(s):  
John C Stevenson
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Hormone Replacement Therapy ◽  
Primary Prevention ◽  
Replacement Therapy ◽  
Women's Health ◽  
Consensus Statement ◽  
Hormone Replacement ◽  
Women's Health Initiative ◽  
Health Initiative

The British Menopause Society Council is committed to provide up to date authoritative reviews to aid health professionals to inform and advise women about key issues in postreproductive health. Coronary heart disease is a leading cause of death in women. Observational studies have consistently shown estrogen to help prevent coronary heart disease in postmenopausal women. The large randomized controlled Women’s Health Initiative trial initially did not confirm these observational findings. However, further analyses of the Women’s Health Initiative study as well as meta-analyses of randomized clinical trials of hormone replacement therapy and of the observational Nurses’ Health Study have now found that the timing of onset of hormone replacement therapy use is important and that estrogen may have an important protective role in coronary heart disease, particularly in women initiating treatment below age 60 years. This consensus statement will examine the evidence regarding hormone replacement therapy and non-estrogen therapies (lipid-lowering agents, aspirin, antihypertensives, anti-diabetic medications, selective estrogen receptor modulators) as well as diet, lifestyle and smoking cessation in the primary prevention of coronary heart disease in women.

Combined continuous hormone replacement therapy: an update

1997 ◽  
Vol 6 (1) ◽  
pp. 1-22
Author(s):  
Laurence C Udoff ◽  
Eli Y Adashi
Keyword(s):  
Hormone Replacement Therapy ◽  
Cognitive Functioning ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Vasomotor Symptoms ◽  
Oestrogen Replacement Therapy ◽  
Urogenital Atrophy ◽  
Cardiovascular Morbidity And Mortality ◽  
Growing Body ◽  
Prevention Of Osteoporosis

A growing body of information now supports the theory that oestrogen replacement therapy can substantially eliminate or attenuate the complications incurred as a result of the menopause. In particular, data support the claim that oestrogen replacement therapy for postmenopausal women is associated with the relief of vasomotor symptoms, the prevention of osteoporosis and urogenital atrophy, a lowering of cardiovascular morbidity and mortality, improved cognitive functioning, and a lower incidence of Alzheimer's disease.

Consensus statement for non-hormonal-based treatments for menopausal symptoms

2017 ◽  
Vol 23 (2) ◽  
pp. 71-75 ◽  
Author(s):  
Jane Woyka
Keyword(s):  
Hormone Replacement Therapy ◽  
Reproductive Health ◽  
Replacement Therapy ◽  
Hormonal Therapy ◽  
Consensus Statement ◽  
Hormone Replacement ◽  
Clinical Excellence ◽  
Menopausal Symptoms ◽  
Evidence Based

Since the June 2014 consensus statement published in Post Reproductive Health we have had definitive guidelines on menopause treatment from the National Institute for Clinical Excellence in November 2015. These included robust and evidence based information about many non-estrogen based treatments, which are particularly useful for patients who do not wish to take hormone replacement therapy, or who have medical contraindications to hormonal therapy such as hormone dependent cancers. Whilst none of these therapies is as effective as hormones, we must be able to advise patients about them and recommend which treatments may be helpful for individual women.

Managing the Menopause British Menopause Society Council Consensus Statement on Hormone Replacement Therapy

2003 ◽  
Vol 9 (3) ◽  
pp. 129-131
Author(s):  
Joan Pitkin ◽  
Margaret C P Rees ◽  
Sarah Gray ◽  
Mary Ann Lumsden ◽  
John Stevenson ◽  
...  
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Consensus Statement ◽  
Hormone Replacement
Sign in / Sign up

Export Citation Format

Share Document